Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Generic statins are the standard of care for 3 million Americans affected annually by dyslipidemia. Approximately 20% of these individuals are intolerant, and PCSK9 inhibitors provide an effective alternative. Recent drug launches (such as sofosbuvirir) have raised Payer scrutiny regarding drug pricing, triggering proactive review of therapies, such as PCSK9 inhibitors, which could pose considerable budget impact.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
